Bank Pictet & Cie Europe AG Reduces Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Bank Pictet & Cie Europe AG lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 48.9% during the 4th quarter, HoldingsChannel reports. The fund owned 1,501 shares of the life sciences company’s stock after selling 1,436 shares during the period. Bank Pictet & Cie Europe AG’s holdings in Illumina were worth $201,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in ILMN. Versant Capital Management Inc lifted its position in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares in the last quarter. Golden State Wealth Management LLC purchased a new stake in shares of Illumina during the fourth quarter worth $32,000. TD Private Client Wealth LLC lifted its position in shares of Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after acquiring an additional 141 shares in the last quarter. V Square Quantitative Management LLC lifted its position in shares of Illumina by 50.6% during the fourth quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock worth $52,000 after acquiring an additional 132 shares in the last quarter. Finally, Private Trust Co. NA lifted its position in shares of Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after acquiring an additional 212 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 1.5 %

ILMN opened at $100.24 on Friday. The company has a market cap of $15.88 billion, a P/E ratio of -13.05 and a beta of 1.10. The business’s 50-day moving average price is $132.74 and its 200-day moving average price is $134.74. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 12 month low of $99.35 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. On average, equities analysts expect that Illumina, Inc. will post 4.42 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ILMN. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and decreased their price target for the stock from $177.00 to $140.00 in a report on Friday, February 7th. UBS Group upped their price target on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Royal Bank of Canada decreased their price target on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Canaccord Genuity Group decreased their price target on shares of Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a report on Friday, February 7th. Finally, JPMorgan Chase & Co. upped their price target on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $159.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.